Peptides DB
Research-centric peptide and protocol reference hub

GHK-Cu vs TB-500 Ac-LKKTETQ

Updated November 6, 2026 · Reviewed by the PeptidesDB Editorial team

GHK-Cu: Research use — not FDA-approvedTB-500 Ac-LKKTETQ: Research use — not FDA-approved

A data-driven comparison of GHK-Cu and TB-500 Ac-LKKTETQ (also searched as TB-500 Ac-LKKTETQ vs GHK-Cu) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

GHK-Cu centers on skin, while TB-500 Ac-LKKTETQ leans toward healing. On indexed research, GHK-Cu is ahead (GHK-Cu: 27 studies, Preclinical; TB-500 Ac-LKKTETQ: 10, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • •GHK-Cu is strongest for skin; TB-500 Ac-LKKTETQ for healing.
  • •Evidence: GHK-Cu Preclinical (27 studies) vs TB-500 Ac-LKKTETQ Human evidence (10).
  • •Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

GHK-CuTB-500 Ac-LKKTETQ

At a glance

GHK-CuPreclinical

Copper-binding | Skin and wound healing

Strongest: SkinStudies: 27Level: Preclinical
TB-500 Ac-LKKTETQHuman evidence

Healing | Tissue repair and regeneration

Strongest: HealingStudies: 10Level: Limited Research

GHK-Cu vs TB-500 Ac-LKKTETQ: side-by-side

MetricGHK-CuTB-500 Ac-LKKTETQ
ClassHealingHealing
Regulatory statusResearch use onlyResearch use only
Evidence gradePreclinicalHuman evidence
Studies indexed2710
Research levelPreclinicalLimited Research
Strongest effectSkin & aestheticsHealing & recovery
Healing & recovery5.0▲5.0▲
Muscle & body comp1.03.0▲
Metabolic & appetite2.0▲2.0▲
Neuro & mood1.0▲1.0▲
Sleep & circadian0.01.0▲
Inflammation & immune4.0▲4.0▲
Skin & aesthetics5.0▲2.0

▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).

Mechanism & pharmacokinetics

PropertyGHK-CuTB-500 Ac-LKKTETQ
MechanismCopper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signalingActin-sequestering peptide; promotes cell migration & angiogenesis
RouteTopical / subcutaneousSubcutaneous injection (research use)

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is GHK-Cu?

Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.

Full GHK-Cu profile, mechanism & studies →

What is TB-500 Ac-LKKTETQ?

Thymosin Beta-4 Active Fragment | Healing Peptide

Full TB-500 Ac-LKKTETQ profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingEvenBoth ~5.0/5
MuscleTB-500 Ac-LKKTETQ3.0/5 effect signal
MetabolicEvenBoth ~2.0/5
NeuroEvenBoth ~1.0/5
SleepTB-500 Ac-LKKTETQ1.0/5 effect signal
InflammationEvenBoth ~4.0/5
SkinGHK-Cu5.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack GHK-Cu and TB-500 Ac-LKKTETQ?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

GHK-Cu vs TB-500 Ac-LKKTETQ: side effects

GHK-Cu

No community-reported effects logged yet.

TB-500 Ac-LKKTETQ

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

GHK-Cu has 27 approved studies indexed (Preclinical), and TB-500 Ac-LKKTETQ has 10 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is GHK-Cu or TB-500 Ac-LKKTETQ better?

It depends on your goal. GHK-Cu is strongest for skin; TB-500 Ac-LKKTETQ for healing. GHK-Cu has more indexed studies (27). See the goal-by-goal breakdown above.

Is GHK-Cu or TB-500 Ac-LKKTETQ better for weight loss?

They score similarly on the metabolic/appetite axis in the community data.

Is GHK-Cu or TB-500 Ac-LKKTETQ better for muscle?

TB-500 Ac-LKKTETQ leads on the muscle & body-composition axis (3.0/5).

Which has more research, GHK-Cu or TB-500 Ac-LKKTETQ?

GHK-Cu has 27 approved studies indexed (Preclinical); TB-500 Ac-LKKTETQ has 10 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack GHK-Cu and TB-500 Ac-LKKTETQ?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of GHK-Cu vs TB-500 Ac-LKKTETQ?

GHK-Cu: no community-reported effects logged yet. TB-500 Ac-LKKTETQ: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is GHK-Cu or TB-500 Ac-LKKTETQ FDA-approved?

GHK-Cu is a research-use compound and is not FDA-approved. TB-500 Ac-LKKTETQ is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is TB-500 Ac-LKKTETQ better than GHK-Cu?

For healing, TB-500 Ac-LKKTETQ has the edge; for skin, GHK-Cu does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

GHK-Cu and TB-500 Ac-LKKTETQ are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 6, 2026.